Saffron is best known as the world's most expensive spice, but it is also one of the few botanicals with a genuine track record in mood research. A brand new 2026 trial, published this year in the journal Frontiers in Nutrition, adds a specific and useful piece to that record. It asked whether a standardized saffron extract could lift low mood in women aged 50 to 70, a group living through the years around and after menopause, when low mood and poor sleep are especially common. The answer was a cautious yes on the main measure, along with a few interesting extras and some honest limits. Here is exactly what the study found, why this age group matters, how strong the evidence really is, and how people use saffron sensibly.
The benefit, in plain terms
Researchers gave 86 women aged 50 to 70 either a standardized saffron extract (28 mg a day) or a look-alike placebo for 12 weeks, with neither the women nor the researchers knowing who got which. The women on saffron reported a bigger drop in low-mood symptoms than the women on placebo. The effect was modest, not dramatic: close to half the saffron group felt a meaningful improvement, versus about a quarter on placebo. Two other measures, self-esteem and daytime tiredness, also nudged in saffron's favor, but the researchers flagged those as early, exploratory findings that need confirming. Saffron did not improve measured sleep quality or skin. And this was a small, industry-funded study, so the fair way to read it is as one promising data point, not proof.
The new study, in one paragraph
A 2026 randomized, double-blind, placebo-controlled trial in Frontiers in Nutrition tested a standardized saffron extract (Affron, 28 mg a day) against placebo in 86 women aged 50 to 70 who had low mood and poor sleep, over 12 weeks. On the main measure, a standard depression questionnaire, the saffron group improved more than placebo (a moderate effect, and a meaningful improvement was about twice as common on saffron, 48.8%, as on placebo, 25.6%). Self-esteem and daytime sleep-related impairment also favored saffron, but the authors describe those as exploratory. The honest catch: the study was funded by Pharmactive, the company that makes the Affron extract, and it was small, so it needs independent replication.
Frontiers in Nutrition, 2026;13:1838513. Randomised, double-blind, placebo-controlled trial, 86 women aged 50 to 70, 12 weeks, 28 mg/day. Industry-funded (Pharmactive). PMID 42389708.
The short version
- A brand new 2026 trial found that 28 mg a day of a standardized saffron extract lowered low-mood scores more than placebo over 12 weeks in women aged 50 to 70.
- The effect was modest, not dramatic: a meaningful improvement was roughly twice as common on saffron (about half the group) as on placebo (about a quarter).
- Self-esteem and daytime tiredness also improved, but those were exploratory extras the authors say need confirming. Saffron did not improve measured sleep quality or skin.
- The big caveat: the study was small and funded by the company that makes the extract, and much of the saffron mood evidence comes from the same research group.
- What steadies it: the result lines up with an earlier trial in midlife women and an independent trial in postmenopausal women, so it is a believable, if not final, signal.
What the 2026 trial actually found
The cleanest way to read this study is to look at every outcome it measured, the wins and the misses together, because that is where a lot of saffron coverage gets carried away. Here is the full scorecard.
| What was measured | What the trial found |
|---|---|
| Low mood (the main measure) | Improved on saffron vs placebo. Moderate effect, statistically significant. A meaningful improvement was about twice as common on saffron. |
| Self-esteem | Improved on saffron. Exploratory secondary finding the authors say needs confirming. |
| Daytime sleep-related impairment | Improved on saffron. Also an exploratory secondary finding. |
| Sleep disturbance (actual sleep quality) | No significant difference from placebo. |
| Self-rated physical appearance | No significant difference. |
| Estimated facial skin age (AI tool) | No significant difference. |
The headline finding is the low-mood result, and it is worth understanding in plain terms. The women filled out a well-established mood questionnaire (the depression part of a standard scale called the DASS-21), where higher scores mean more low-mood symptoms. The saffron group's scores fell further than the placebo group's, by a moderate amount in statistical terms (Cohen's d of 0.48). The most relatable number is the responder rate: the researchers set a bar for a "clinically meaningful" improvement, one big enough that a person would likely notice she felt better, and 48.8% of the saffron group cleared that bar versus 25.6% on placebo. In other words, meaningful improvement was roughly twice as common on saffron.
A useful way to translate that gap is the number needed to treat. The difference between the two groups was about 23 percentage points, which works out to roughly one extra woman reaching a meaningful improvement for every 4 to 5 who took saffron instead of placebo. That is a respectable number for a nutritional supplement, but notice the flip side: about a quarter of the placebo group improved too, a normal reminder that low mood can lift on its own over 12 weeks with time, attention, and the placebo effect.
The two exploratory extras, self-esteem (measured with the Rosenberg scale, a standard read on how a person feels about their own worth) and daytime sleep-related impairment (how much tiredness got in the way of daily life), both moved in saffron's favor. Those are genuinely interesting, and self-esteem in particular is an unusual thing to measure in a saffron trial. But the authors are careful to call them exploratory, meaning promising signals that need confirming in a study designed around them, not settled conclusions. And it is important to read the misses honestly: saffron did not improve the women's actual sleep-quality score, their view of their own appearance, or an AI estimate of their skin age. So this is a mood result, not a sleep-fixing or beauty result.
Why study women aged 50 to 70
The choice of population is not random, and it is part of what makes this study interesting. There is a well-documented window of raised mood vulnerability that runs from perimenopause, the transition leading up to the final period, into the early postmenopausal years. During this stretch, estrogen does not simply glide downward. It swings and fluctuates, and because estrogen interacts with brain chemicals tied to mood and sleep, these hormonal ups and downs are linked to a greater likelihood of low mood, irritability, and disrupted sleep for many women. Reviews of the menopausal transition describe it plainly as a period when some women, including those with no prior history of depression, face elevated risk compared with their earlier years.
Low mood in this age group is also easy to overlook. Fatigue, irritability, trouble sleeping, and a fading of enjoyment often get waved off as "just menopause," "just stress," or "just getting older," by women themselves and sometimes by busy clinicians. That combination, common and easy to miss, is exactly why researchers are interested in accessible, well-tolerated options and in studying this specific group rather than a generic mixed-age sample. If you want the wider picture on this life stage, our guide to supplements for menopause and our post on navigating menopause both cover it in more depth. None of this means saffron treats menopause or any hormonal condition. It simply explains why this is a sensible place to study general mood and wellbeing.
How strong is the evidence, really
This is where honesty matters most, because saffron headlines tend to run ahead of the data. A few things to hold in mind at once.
The effect is modest. In statistical terms the mood benefit was a moderate effect (a Cohen's d of 0.48, at the low end of the moderate range). That is meaningful and worth reporting, but it is not a dramatic, life-changing shift, and it sits in the same range as many other well-studied mood and lifestyle interventions. A moderate effect also means a lot of overlap between the groups: plenty of people on placebo did fine, and not everyone on saffron improved.
The funding is a real conflict of interest. The trial was paid for by Pharmactive, the company that makes the specific Affron extract being tested, and the funder helped design the study. That does not automatically invalidate the results, and the investigators say they ran the analysis independently, but it is a genuine bias worth naming plainly. On top of that, a large share of the Affron mood evidence, including an earlier trial in midlife women, comes from the same two researchers, so there is less fully independent confirmation than the raw study count might suggest.
But it does not stand alone. Two things raise confidence above "single sponsored study." First, this result is a replication: the same group ran an earlier randomized trial of the same Affron extract in perimenopausal women and found the same pattern, a clear improvement in psychological symptoms (with about a third drop in anxiety and depression scores) but no benefit for physical menopausal symptoms. Second, and more importantly, an independent team with no tie to the manufacturer tested a different saffron extract at a similar dose (30 mg) in postmenopausal women, this time with diagnosed depression, and also found a significant improvement in depression scores. When manufacturer-funded and independent trials point the same direction, the signal is more believable.
Zoom out to the whole body of evidence and the picture is consistent but hedged. A meta-analysis pooling many saffron trials found a large average benefit for depressive symptoms versus placebo, though the same authors flagged publication bias, meaning the true effect is probably smaller than the pooled number looks. And in head-to-head trials, a 2025 meta-analysis found no significant difference between saffron and standard antidepressants (SSRIs) for depression symptoms, with saffron causing fewer side effects. That is a striking finding, but read it carefully: those were trials in mild-to-moderate cases, and it is a reason researchers keep studying saffron, not a basis for choosing it over a prescription. For the full landscape, see our complete guide to saffron for mood.
How saffron may help mood
The reason any of this is plausible is that saffron is not an inert spice. Researchers have proposed a couple of ways it might support mood, though it is important to stress these are proposed mechanisms, not fully established in humans.
The first is serotonergic activity. Serotonin is a brain chemical closely tied to mood, and laboratory and animal work suggests saffron's active compounds, mainly crocin and safranal, may influence serotonin signaling, for instance by slowing how quickly it is cleared from between nerve cells. This is loosely described as a natural echo of how some mood medications work, and it is also the reason for the big caution about combining saffron with antidepressants. But the effect is gentler and far less mapped out than a pharmaceutical, so the comparison should not be overstated. The second proposed pathway is antioxidant and anti-inflammatory activity. Saffron's red and gold pigments are strong antioxidants, and because oxidative stress and low-grade inflammation have been linked to low mood, the idea is that saffron may help buffer those processes. Both explanations are plausible and rest mostly on early and preclinical work. The honest summary is that the mechanism is multi-pronged and not fully nailed down, which is typical for plant compounds.
The dose that was studied
The trial used 28 mg a day of Affron, a specific standardized saffron extract, taken as a single daily dose. That lines up with the wider research: most saffron mood studies use about 28 to 30 mg a day of a standardized extract, usually a whole-stigma extract standardized to its active compounds. The number that actually matters is the standardization, the guaranteed level of the active compounds, because that is what makes one capsule comparable to the next and to the doses used in trials. The pinch of saffron used in cooking is far below the studied amount and will not do what these studies describe.
Two practical points. Saffron is not a fast switch: the trials run 6 to 12 weeks with benefits building gradually, so plan on at least a couple of months of daily use before deciding whether it does anything for you. And because real saffron is expensive, adulteration and dilution are common, which is another reason to buy a well-characterized extract from a brand that tests its material rather than a cheap generic powder.
Safety and cautions
At the studied dose of roughly 28 to 30 mg a day, saffron is generally well tolerated, and the side effects reported in trials are usually mild, such as nausea, headache, appetite changes, or drowsiness. Supplement doses are also tiny compared with the level at which saffron becomes a real problem. Still, a few cautions matter.
- Antidepressants and other serotonergic medications. This is the big one. Because saffron appears to act partly on serotonin, layering it on top of an SSRI, an SNRI, or another serotonergic drug could in theory push serotonin activity too high. Do not combine them on your own. This is a conversation for the doctor who prescribed the medication.
- Pregnancy. Avoid saffron supplements. In larger amounts it can stimulate the uterus, and it is traditionally avoided in pregnancy.
- Blood thinners and blood-pressure medication. Saffron may have mild effects on bleeding and blood pressure, so check with a clinician if you take these.
- Authenticity. Because real saffron is costly, adulteration is common. Buy from a brand that tests for identity and purity.
And the point worth repeating: this is about supporting everyday mood, not treating a diagnosis. Persistent low mood deserves a proper evaluation. If you are weighing options, our low mood guide covers the wider picture of what the evidence supports.
Products worth considering
The trial used Affron, a specific standardized saffron extract, at 28 mg a day. If you want to match what was studied, that word on the label is the thing to look for. Here are four options, three of them the exact Affron extract and one a budget standardized-saffron alternative. None of these is a treatment for depression, and if you take an antidepressant, read the cautions above first.
Frequently asked questions
Does saffron actually help with low mood?
The evidence is better than for most mood supplements, but it is modest. A 2026 trial in women aged 50 to 70 found that 28 mg a day of a standardized saffron extract lowered depression-questionnaire scores more than placebo over 12 weeks, and several earlier trials and meta-analyses point the same way. The effect is real but moderate, it does not help everyone, and it applies to mild-to-moderate low mood, not clinical depression.
How much saffron did the study use, and what kind?
The trial used 28 mg a day of Affron, a specific standardized saffron extract, taken as a single daily dose for 12 weeks. Most saffron mood research uses about 28 to 30 mg a day of a standardized extract, so the type and standardization matter more than the raw milligrams. The tiny pinch of saffron used in cooking is far below the studied amount.
Can I take saffron with my antidepressant?
Only with your prescriber's guidance. Saffron appears to act partly on serotonin, the same system many antidepressants target, so combining them could in theory push serotonin activity too high. Do not add saffron on top of an SSRI or other antidepressant on your own. Talk to the doctor who prescribed it first.
Did the study show saffron improves sleep or skin?
Not in the way the headlines might suggest. Saffron improved daytime sleep-related impairment, meaning how much tiredness interfered with daily life, but it did not significantly improve measured sleep disturbance, the actual quality-of-sleep score. It also had no effect on self-rated physical appearance or an AI-estimated skin age. So the honest reading is a mood benefit, not a sleep-quality or beauty benefit.
Is this study strong enough to rely on?
Treat it as one promising data point. It was a small trial of 86 women, and it was funded by Pharmactive, the company that makes the Affron extract, which is a genuine conflict of interest. Much of the Affron mood evidence comes from the same research group. What raises confidence is that the result lines up with an independent trial in postmenopausal women and with broader saffron meta-analyses, but it still needs replication by unrelated teams.
Can saffron replace an antidepressant?
No. This research is about mild-to-moderate low mood, not clinical depression, and saffron is a dietary supplement, not a substitute for medical care. In head-to-head trials saffron has performed comparably to low doses of some antidepressants with fewer side effects, which is interesting, but that is not a reason to stop or change a prescribed medication. Any changes to depression treatment should be made with your doctor.
The bottom line
The 2026 trial is a real, if modest, addition to the saffron mood story. In women aged 50 to 70 with low mood and poor sleep, 28 mg a day of a standardized saffron extract lowered low-mood scores more than placebo over 12 weeks, and meaningful improvement was about twice as common on saffron. Self-esteem and daytime tiredness improved too, though those are exploratory, and saffron did nothing measurable for sleep quality or appearance. Read honestly, the study is small and industry-funded, and much of the Affron evidence comes from one group, which is why the independent trial in postmenopausal women and the broader meta-analyses matter: they keep this from resting on a single sponsored result. The sensible takeaway is that saffron is one of the better-evidenced mood supplements, worth a two-month trial at the studied dose if low mood is mild-to-moderate, never a replacement for professional care, and never something to stack on an antidepressant without your doctor.